HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Immunotherapy: Vaccine trials in melanoma -- time for reflection.

AbstractThe disappointing results of the large, randomized, controlled trials showing no benefit of vaccines in patients with advanced and metastatic melanoma call for a reassessment of the development of therapeutic vaccines and the importance of better immune monitoring methodology, such as adoptive T-cell therapy with lymphodepletion.
AuthorsAlexander M M Eggermont (Affiliation: Department of Surgical Oncology, Daniel den Hoed Cancer Center, Erasmus University MC, Rotterdam, The Netherlands. a.eggermont at erasmusmc.nl)
JournalNature reviews. Clinical oncology (Nat Rev Clin Oncol) Vol. 6 Issue 5 Pg. 256-8 (May 2009) ISSN: 1759-4782 [Electronic] England
PMID19390551 (Publication Type: Comment, Journal Article)
Chemical References
  • Cancer Vaccines
  • Interleukin-2
Topics
  • Cancer Vaccines (administration & dosage, immunology)
  • Dose-Response Relationship, Drug
  • Humans
  • Immunotherapy
  • Interleukin-2 (therapeutic use)
  • Melanoma (pathology, secondary, therapy)
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Randomized Controlled Trials as Topic
  • Skin Neoplasms (pathology, therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $45.00 USD